In the BioHarmony Drug Report Database

"Preview" Icon

Anlotinib

Tasigna (anlotinib) is a small molecule pharmaceutical. Anlotinib was first approved as Tasigna on 2007-11-19. It has been approved in Europe to treat bcr-abl positive chronic myelogenous leukemia. It is known to target vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 3, fibroblast growth factor receptor 1, and vascular endothelial growth factor receptor 1.

 

Trade Name

 

Tasigna
 

Common Name

 

anlotinib
 

ChEMBL ID

 

CHEMBL3545021
 

Indication

 

bcr-abl positive chronic myelogenous leukemia
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Anlotinib structure rendering